X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

BMG Pharma’s nasal spray, mouth rinse achieve efficacy in preventing COVID-19

Content Team by Content Team
5th August 2021
in News
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Milan headquartered biopharmaceutical and B2B company BMG Pharma with its chemical plant in Torviscosa (Italy), conducted a clinical study with encouraging results to assess the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse in the treatment of asymptomatic COVID-19 patients.

These positive results could represent the starting point for the use of the products in the prevention as well as the early treatment of several infections such as SARS-CoV-2 and the reduction of risk of infection and spread of the virus. The efficiency of the tested products is based on the action of hydrogen peroxide combined with hyaluronic acid.

BMG0705 Nasal Spray is based on a patented nasal spray formulation, with the disinfecting action of hydrogen peroxide and hyaluronic acid creating a protective barrier: the barrier, adhering to the nasal mucosa, can stop COVID-19 and other infections and prevents them from worsening.

Similarly, BMG0703A Mouth Rinse forms a protective film that adheres to the oral mucosa preventing further irritations, acting against external agents and helps to prevent complications caused by infections in the oral cavity such as seasonal flu and SarsCov-2.

The study enrolled a total of 106 people, who completed an experimental protocol in the second quarter of 2021. The random allocation presented sufficient efficiency, as the associations between the trial arm and covariates showed P values greater than 0.05. In the placebo arm, 57.6 per cent of people had a positive PCR swab test following the index positive test, whereas in the active intervention arm that proportion was 31.9 per cent, with a P value for the difference of 0.008. All subjects declared to have adhered to the study protocol and to have followed the prescription carefully (three full days of therapy) with no side effects.

The results from the analysis suggest that the active intervention under investigation can be effective in increasing the negativistic rate of a positive PCR nose swab test for SARS-CoV-2. Further research is needed to confirm these results in some population subgroups.

Previous Post

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

Next Post

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In